NCT06042569 2026-04-17
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
City of Hope Medical Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT07460752 2026-03-10
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
Mayo Clinic
Phase 2 Not yet recruiting
NCT01334021 2026-03-09
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07407920 2026-02-12
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03624478 2025-11-26
Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery
Mayo Clinic
Phase 2 Completed
NCT07191717 2025-11-10
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT04329065 2025-11-06
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
Phase 2 Recruiting
NCT04249622 2025-09-16
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT05595499 2025-07-02
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting